Literature DB >> 2873593

Are serotonergic neurons involved in the control of anxiety and in the anxiolytic activity of benzodiazepines?

M H Thiebot.   

Abstract

Several studies have shown that, like benzodiazepines (BZP), treatments able to reduce or block the activity of CNS serotonergic (5-HT) neurons released punished behavior. Therefore, 5-HT mechanisms have been tentatively implicated in the anti-punishment (anxiolytic?) activity of BZP. Numerous data, however, are not in keeping with this hypothesis. Since not responding enables the animals to avoid punishment but also delays the receipt of food-reward, one of these factors could be an alteration of waiting capacities. Indeed, we have shown that diazepam released behavioral suppression in conflict schedules only when the duration of the punished periods exceeded 1 minute. Moreover, in rats allowed to choose in a T-maze between immediate-but-small vs. delayed-but-large reward, BZP significantly decreased the frequency with which the delayed reward was chosen, with 5-HT uptake blockers producing opposite effects. Therefore, one can hypothesize that BZP render the animals less prone than controls to tolerate delay of reward and that 5-HT mechanisms may be involved in this phenomenon. An altered tolerance to delay of reward should be taken into account when interpreting the BZP-induced release of behavioral inhibition in classical conflict procedures.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873593     DOI: 10.1016/0091-3057(86)90214-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  15 in total

1.  Hypersensitivity due to stress.

Authors:  G Hampf
Journal:  Anesth Prog       Date:  1989 Nov-Dec

2.  The influence of psychotropic drugs on the ultrasonic calling of mouse pups.

Authors:  D Benton; K Nastiti
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  5HT drugs in animal models of anxiety.

Authors:  S L Handley; J W McBlane
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Effect of lesions of the ascending 5-hydroxytryptaminergic pathways on choice between delayed reinforcers.

Authors:  M A Wogar; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.

Authors:  I K Wright; M Heaton; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  5-HT1A receptor blockade reverses GABA(A) receptor alpha3 subunit-mediated anxiolytic effects on stress-induced hyperthermia.

Authors:  Christiaan H Vinkers; Ruud van Oorschot; S Mechiel Korte; Berend Olivier; Lucianne Groenink
Journal:  Psychopharmacology (Berl)       Date:  2010-06-10       Impact factor: 4.530

7.  Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze.

Authors:  I K Wright; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats.

Authors:  C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

9.  Buspirone, gepirone, ipsapirone, and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-s schedule when compared with 5-HTP and diazepam.

Authors:  J B Richards; K E Sabol; T H Hand; D C Jolly; G J Marek; L S Seiden
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

10.  Potential anxiolytic properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin 1A receptor agonist.

Authors:  M Carli; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.